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Abstract
The ability to conduct weight-of-evidence assessments to inform the assessment of potential
environmental neurotoxicants is limited by lack of comparability of study methods, data analysis,
and reporting. There is a need to establish consensus guidelines for conducting, analyzing, and
reporting neurodevelopmental environmental epidemiologic studies, while recognizing that
consistency is likewise needed for epidemiology studies examining other health outcomes. This
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paper proposes a set of considerations to be used by the scientific community at-large as a tool for
systematically evaluating the quality of proposed and/or published studies in terms of their value
for weight-of-evidence assessments. Particular emphasis is placed on evaluating the sensitivity and
specificity of neurodevelopmental function tests, as these characteristics directly affect the risk of
false positive and false negative decisions at the level of the individual, thus influencing the risk of
incorrect conclusions at the level of study findings. The proposed considerations are the first step
in what must be a larger consensus-based process and can serve to catalyze such a discussion.
Achieving consensus in these types of endeavors is difficult; however, opportunities exist for
further interdisciplinary discussion, collaboration, and research that will help realize this goal.
Broad acceptance and application of such an approach can facilitate the expanded use of
environmental epidemiology studies of potential neurodevelopmental toxicants in the protection of
public health, and specifically children's health.
Keywords
neurodevelopmental function tests; interstudy consistency; environmental epidemiology; weight-
of-evidence assessments; risk assessment; environmental chemicals
1. Introduction
Pediatric neurodevelopmental disorders have generated substantial attention from the
scientific community, the public and media. This high visibility is due in part to an observed
increased prevalence of autism spectrum disorders (Rice et al., 2010) and possibly attention
deficit hyperactivity disorder (ADHD) (Pastor and Reuben, 2008). Many chemicals are
known to be human neurotoxicants, at least following acute exposure to adults (Grandjean
and Landrigan, 2006). In addition, associations between specific environmental chemicals
and neuropsychiatric disorders have been reported (e.g., depression and air pollutants
(Szyszkowicz et al., 2009); anxiety and PCB 153 (Plusquellec et al., 2010); ADHD and
polyfluoroalkyl chemicals (Hoffman et al., 2010); ADHD and PCBs and lead (Eubig et al.,
2010); autism and pesticides (Roberts et al., 2007)).
In spite of the growing concerns about perturbations in neurodevelopment that may be
associated with environmental exposures, few environmental chemicals are regulated on the
basis of neurodevelopmental outcomes. A review of the U.S. Environmental Protection
Agency (US EPA) Integrated Risk Information System (IRIS) database illustrated the
limited impact of studies assessing neurodevelopmental endpoints in children have had on
the characterization of hazards resulting from early life stage exposures to environmental
toxicants. The IRIS database is a publicly available peer-reviewed source of toxicological
information maintained by the US EPA for over 550 environmental chemicals (US EPA,
2010). For those chemical assessments that were issued in 1997 or later (a total of 86, listed
in Table 1), detailed hazard and dose response information is provided in a “Toxicological
Review,” thereby allowing an examination of the use and influence of neurobehavioral data
in oral and inhalation reference value derivation. Out of the 86 assessments examined, 19
had no neurotoxicity data in either animals or humans, 25 had only animal but not human
neurotoxicity data, and 33 had adult human neurotoxicity data (30 of which were supported
by animal data). Only 9 of the 86 IRIS toxicological databases that were examined included
any information on neurotoxicity in children, and of those only 3 reported data from actual
neurodevelopmental testing (the others being 2 chemicals with reports of congenital
anomalies and 4 chemicals with case reports in children that suggested effects on the
nervous system). The chemicals for which neurodevelopmental testing was conducted were
methyl mercury, perchloroethylene, and trichloroethylene. While these data were in all cases
considered qualitatively important in the weight-of-evidence evaluation of the chemical
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toxicity profile, methyl mercury was the only final assessment for which
neurodevelopmental testing data in children were actually used as the quantitative basis for a
reference value.
For these particular examples, the use of the data from neurobehavioral testing in children
was limited for reference value derivation by a number of considerations related to study
conduct or data reporting. These included issues such as adequacy of sample size,
inconsistent testing methodologies, questions about the selection or implementation of
testing procedures, inadequate consideration of confounding factors, uncertainties regarding
exposure characterization, reproducibility of study findings, and inconsistencies due to
timing of exposure or life stage of assessment. For two of the draft assessments
(perchloroethylene and trichloroethylene) that included neurodevelopmental data in
children, other toxicological outcomes were observed at lower exposure levels and thus were
selected to derive reference values (US EPA, 2008, 2010). It is important, however, to
recognize the possibility that the full range of neurobehavioral outcomes at the lower end of
the dose-response array may not have been fully characterized, thus limiting the weight-of-
evidence evaluation of the data, and/or selection of the point of departure.
There are several factors that limit consideration of neurodevelopment in weight-of-
evidence assessments. First, neurobehavioral testing in children is not mandated by any
regulatory agency. Second, studies in animals may not fully capture the range of adverse
outcomes in neurological development that might be observed in children. In fact, it has
been noted that developmental neurotoxicity might not be evident in routine toxicology tests
(Landrigan and Grandjean, 2006; Raffaele et al., 2010). Third, use of epidemiology data in
weight-of-evidence assessments has been hindered by differences in methods used in
conducting neurodevelopmental epidemiologic studies as well as differences in data analysis
and reporting (Goodman et al., 2010; Youngstrom et al., 2010).
To address these and related issues, a symposium on “Advancing Neurodevelopmental
Evaluation in Children: An Interdisciplinary Approach” was held on June 29, 2010 at the
joint 34th annual Neurobehavioral Teratology Society, 50th annual Teratology Society, and
23rd annual Organization of Teratology Information Specialists meetings, in Louisville, KY.
The objective of the symposium was to present recent multidisciplinary research centered on
advancing epidemiological evaluation of children for the detection of neurobehavioral
effects potentially associated with exposure to environmental chemicals and the application
of these data to human health risk assessment. The symposium presentations included a
critical review of commonly used neurodevelopmental tests in epidemiological studies of
associations between environmental chemical exposure and adverse health effects, and tests
that should be considered for future studies (Youngstrom et al., 2010; Kenworthy et al.,
2010; Anthony et al., 2010); a critical review of tests used in environmental epidemiology
studies of PCBs (Goodman, 2010; Goodman et al., 2010); discussion of a 2009
interdisciplinary Needs Assessment Workshop which resulted in innovative thinking about
paths forward for neurodevelopmental function testing in environmental epidemiology
(LaKind et al., 2010); and considerations for selection, administration, and interpretation of
neurodevelopmental tests in studies of environmental chemicals. The symposium provided a
forum for further discussion on advancing the science of environmental
neurodevelopmental/ epidemiological research.
A crucial finding of the analysis of epidemiology literature on PCBs and neurodevelopment
was that our ability to conduct weight-of-evidence assessments, even with several studies, is
limited when study methods, data analysis, and reporting lack comparability (Goodman et
al., 2010). Goodman et al. (2010) called for establishing consensus standards for the
conduct, analysis, and reporting of neurodevelopmental environmental epidemiologic
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studies with the recognition that consistency is needed for epidemiology studies examining
other outcomes, as well. Youngstrom et al. (2010), in their assessment of use of
neurodevelopmental function tests used in environmental epidemiology, noted that “the field
of environmental epidemiology may be nearing a stage where a formal set of reporting
guidelines could be developed to help the design of future studies, as has been done with
clinical trials, studies of diagnostic assessment tools, and medical epidemiological studies.”
We attempted to address these issues by proposing a set of considerations to be used by the
scientific community at-large as a tool for systematically evaluating the quality of proposed
and/or published studies in terms of their value for weight-of-evidence assessments. We
specifically propose considerations and quality criteria for epidemiological research in the
area of neurodevelopmental disorders and exposure to chemicals. Particular emphasis is
placed on evaluating the sensitivity and specificity of the measures, as these characteristics
directly affect the risk of false positive and false negative decisions at the level of the
individual, thus influencing the risk of incorrect conclusions at the level of study findings.
We recognize that the considerations proposed here, which we refer to as HONEES
(Harmonization of Neurodevelopmental Environmental Epidemiology Studies), are the first
steps in what must be a larger consensus-based process. We hope that this serves to catalyze
such a discussion. Ultimately, the end product – a clearly articulated set of standards and
quality criteria – is intended to help inform the design of proposed studies and to assist
funding agencies in deciding which proposals are most likely to advance the field. Perhaps
most importantly, use of this type of guidance would enhance the ability of scientists to
utilize results from such studies as the National Children's Study
(http://www.nationalchildrensstudy.gov/Pages/default.aspx) for weight-of-evidence
assessments in support of chemical regulation for developmental neurotoxicants.
2. Methods
The proposed considerations are modeled on the STROBE (STrengthening the Reporting of
OBservational studies in Epidemiology) guidelines (von Elm et al., 2008)
(http://www.strobestatement.org/). They also incorporate elements from the CONSORT
(Consolidated Standards of Reporting of Trials) criteria for clinical trials (Moher et al.,
2001), the STARD criteria (Standards for Reporting of Diagnostic Accuracy) for assessment
studies (Bossuyt et al., 2003), the Evidence Based Medicine criteria for the validity of a
study of harm (Straus et al., 2005), and prior recommendations from the fields of toxicology
and psychology (Youngstrom et al., 2010). These considerations were gathered, reviewed
for relevance, and then collated into a more relevant set of recommendations focused on
epidemiological studies related to neurodevelopment and chemical exposures.
For the purposes of reporting and evaluating studies of the neurodevelopmental effects
associated with toxicant exposure, the STROBE guidelines provide an excellent starting
point. STROBE includes both general recommendations and specific criteria that are
relevant to longitudinal cohort studies, case control studies, and cross-sectional studies – the
three major designs used to study neurodevelopmental effects of chemical exposure. For
present purposes, the major contribution of the STROBE guidelines was to increase the
focus on study factors that might change assessment results, such as variables that could
influence the sensitivity or specificity of the assessment to exposure effects.
After comparing the tools available in the literature for evaluating epidemiological studies
(STROBE), studies of diagnostic efficiency (STARD), clinical trials (CONSORT), and
recent “evidence based assessment” reviews in psychology (Hunsley and Mash, 2005;
2008), we used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) as the
Youngstrom et al. Page 4













basis for a coding tool (Whiting et al., 2003). The original QUADAS was derived from the
25 criteria in the STARD Guidelines for assessment studies, and the content captured the
major study design and reporting elements that are common to both epidemiological (e.g.,
STROBE) and diagnostic (e.g., STARD) criteria, while also including a stronger emphasis
on exposure and outcome assessment and discriminating accurately between groups. The
QUADAS has been used in multiple reviews and meta-analyses, accumulating a substantial
evidence base supporting its use (Hollingworth et al., 2006; Whiting et al., 2006).
The QUADAS distilled the 25 recommendations from the STARD into 14 key criteria that
could be coded from reports of studies in order to evaluate the quality of the study and
reporting, and the potential for bias to have influenced findings. Two of these 14 criteria did
not appear relevant to studies of environmental chemical exposure. One criterion (QUADAS
#4) pertained to the length of time between the screening and reference standard test. The
intention of Criterion #4 was to capture whether the screening and reference tests were given
close enough together that the person's diagnostic status was unlikely to change in between
test sessions. Treating “diagnostic change over time” as a source of bias does not appear
relevant for studies of environmental chemical exposure both because the central issue is not
agreement between two tests and because the diagnostic status may change over time as a
result of the toxicant exposure. In fact, long-term outcomes may be a central question of
interest, not a source of bias in the study design (e.g., a study may examine the relationship
between a toxicant level in cord blood at birth and the children's later functioning at age 10).
Thus we omitted this criterion from the revised coding tool. Similarly, a second criterion
(QUADAS #7) focused on whether the screening and reference tests were independent of
each other. For purposes of examining neurodevelopmental effects of exposure, the
independence of test results does not appear to be a central design issue (e.g., blood levels
and IQ tests are independent measures).
The Evidence Based Medicine (EBM) guidelines for evaluating the quality of evidence for
studies of harm (Straus et al., 2005) also provided a helpful set of questions and principles
for evaluating studies of effects of chemical exposure. The final augmented set (Table 2)
includes several additional criteria adapted from the EBM guidelines, as denoted in the item
list. These include factors such as whether the subjects were similar in all respects except for
chemical exposure, or whether the neurodevelopmental outcomes were assessed using the
same methods in both the exposed and non-exposed groups (avoiding potential “work-up”
bias).
3. Results
The product of this effort is a set of proposed considerations and recommendations
(HONEES) for a process of selecting a test, evaluating its validity, and presenting findings.
The main areas for evaluation of the study are Sampling and Participants, Assessment
Procedures, and Interpretation and Causal Inference. In the case of the proposed
considerations in Table 2, coding would be accomplished by assigning a numerical value to
a “yes” or “no” response (with the response of “unclear” leading to further evaluation of the
study). The emphasis on criteria and process is consistent with the philosophy of Evidence
Based Medicine and we selected the parameters in Table 2 because they have been refined
over more than a decade of interdisciplinary review, they focus on evaluating and
quantifying the potential risk of harm, and they include study characteristics that influence
estimation of risks. New evidence continues to evolve, and existing tests will continually be
revised or replaced. Thus a canonical list is ultimately a less useful product as it will be
static and will grow ever more dated as the field progresses. Principles and processes, on the
other hand, equip the audience to seek new data, evaluate it, and decide when to change
assessment practices.
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The ultimate goal of conducting neurodevelopmental environmental epidemiology studies is
to improve public health by providing information necessary to determine whether and how
to limit exposures to specific environmental chemicals. However, even multiple, well-
conducted observational studies may not provide regulatory agencies with information
needed for decision-making if the methods used (including methods for measuring and
expressing exposure and methods for examining associations) are not sufficiently consistent
across studies. In epidemiology studies using neurodevelopmental function tests; this
problem is exacerbated by the large number of available test batteries, and associated
differing combinations of subtests (Youngstrom et al., 2010). This has resulted in calls for
establishing consensus standards for the conduct, analysis, and reporting of epidemiologic
studies (Goodman et al., 2010; Goodman, 2010; Bellinger, 2009; Moher et al., 2010).
The proposed considerations in Table 2 are offered as a means of catalyzing the
conversation needed to build a set of consensus standards that can be used by the scientific
community to encourage the type of inter-study harmonization necessary for improved
weight-of-evidence assessments. Ultimately, for such standards to be of value, acceptance
by interested parties, through round-table or consensus conferences involving key scientific
and policy leaders, will be necessary. We are aware of the difficulty in achieving consensus
in these types of endeavors, but opportunities exist for further interdisciplinary discussion,
collaboration, and research that will help realize this goal. Broad acceptance and application
of such an approach can facilitate the expanded use of environmental epidemiology studies
of potential neurodevelopmental toxicants in the protection of public health, and specifically
children's health.
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Table 1
IRIS Chemicals with Toxicological Reviews
No neurotoxicity data in animals or humans
Acrolein Methylene Diphenyl Diisocyanate (monomeric and
polymeric MDI)
Thallium chloride
Bentazon (Basagran) Thallium oxide
Berylliuma Mirexa Thallium selenite
1,3-Butadiene Naphthalenea 1,2,3-Trichloropropane
Chromium(III), insoluble salts Phosgene 2,2,4-Trimethylpentane
Chromium(VI) Propionaldehyde Zinc and compounds
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)a Thallium carbonate
No neurotoxicity data in animals; some data in adult humans (mostly positive); no data in children
Chloroform Hexachlorocyclopentadiene (HCCPD) Thallium nitrate
Animal DNT data (all positive); no adult animal data; no adult or child human data
Beryllium and compounds 1,2-Dibromoethane Perchlorate and Perchlorate saltsa
Chlorite (sodium salt) Diesel engine exhaust 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)
Adult animal data; some DNT data, no human data; results in animals are mixed
Acetonitrile Cyclohexane 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)
Bromobenzene Dibutyl phthalatea
Cerium oxide and Cerium compounds 1,1-Dichloroethylene (1,1-DCE) Phenol
Cis- and trans-1,2-Dichloroethylenea 1,3-Dichloropropene Platinuma
Cumene Ethyl tert-butyl ether (ETBE)a Quinoline
2-Methylnaphthalene Tributyltin oxide (TBTO)
1,3,5-Trinitrobenzene
Neurotoxicity testing in adult animals and data in adult humans (all are positive); a few assessments of DNT in animals; no data in
children
Acetone Chlordecone (Kepone) Nitrobenzene
Acrylamidea n-Hexane 1,1,2,2-Tetrachloroethanea
Barium and Compounds 2-Hexanone Tetrahydrofurana
Benzene Hydrogen cyanidea Thallium(I), soluble salts
Carbon tetrachloridea Methanola Thallium acetate
Chlordane (technical) Methyl chloride Thallium(I) sulfate
Chloroprene Methyl ethyl ketone (MEK) Toluene
Dichloroacetic acid Methyl isobutyl ketone (MIBK) 1,1,1-Trichloroethane
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Neurotoxicity testing in adult animals and data in adult humans (all are positive); a few assessments of DNT in animals; no data in
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Table 2
Proposed Guidance for Evaluating Neurodevelopmental Environmental Epidemiology Studies: Harmonization
of Neurodevelopmental Environmental Epidemiology Studies (HONEES)
Item Yes No Unclear
Sampling & Participants
1.* Were participant selection criteria clearly described?
2.# Were there clearly defined groups of participants, similar in all important ways other than exposure to the
chemical? (e.g. IQ scores, SES, age)
3.* Were the participants representative of the population to whom results would be generalized in practice?
4.* Were withdrawals from the study explained? (e.g., flow diagram, or other accounting)
Assessment Procedures
5.# Were exposures and clinical outcomes measured in the same ways in both groups? (i.e., was the assessment of
outcomes either objective or blinded to exposure?)
6.# Was the follow-up of study participants sufficiently long for the outcome to occur?
7.# Did the follow-up have an acceptable level of participant retention to avoid bias?
8. Did the whole sample (or a random selection of the sample) receive testing using a “gold standard” assessment
tool?
9.* Did participants receive the same assessments regardless of degree of exposure to toxicant?
10.* Was the method for exposure measurement described in enough detail to permit replication or application to
new cases?
11.* Is the assessment tool likely to correctly measure or classify the target construct? (adequate diagnostic
sensitivity and accuracy may be particularly important for neurodevelopmental studies)
12.* Was the neurodevelopmental assessment procedure appropriate?
a. * Were methods described in sufficient detail to permit replication?
b. * Was the test appropriate for the ages at which it was used?
c. * Did the protocol avoid burden or fatigue effects that might invalidate results? (e.g., two hours might be
the upper limit of length for neurodevelopmental assessments of young children; babies need to be in
optimal state before testing can begin)
d. * Are there normative data for comparison, outside of the study of environmental chemicals?
e. * Was the administration valid, or were there major departures from standardization? (e.g., poor training,
used outside of age norms, translated version without supporting psychometric data. Study must
demonstrate evidence of good training, administration, and scoring and checks for continued
administration validity across the length of the study by the review of video tapes or other similar
measures)
13.* Was exposure status determined without knowledge of the results of the neurodevelopmental assessment?
14.* Were the neurodevelopmental assessment results interpreted without knowledge of the exposure status? (e.g.,
blinding of assessment administration and scoring staff; computerized administration)
15.* Was the contextual and supporting information used to interpret the test similar in the research protocol versus
standard clinical practice?
16.* Were uninterpretable/ intermediate test results reported? (e.g., treatment of missing data, and reporting of
borderline or midrange scores versus only extreme groups)
Interpretation and Causal Inference
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Item Yes No Unclear
Sampling & Participants
17.# Do the results of the study fulfill some of the methodological tests for inferring causation?
a.# Is it clear that the exposure preceded the onset of the outcome?
b.# Is there a dose-response gradient?
c.# Is there any positive evidence from other “dechallenge-rechallenge” studies?
d.# Is the association consistent from study to study?
e.# Does the association make biological sense?
*
Adapted from Whiting et al., 2003.
#
Adapted from Straus et al., 2005.
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